Wellbutrin SR Patent Case Will Be Early Application Of Festo Ruling
Executive Summary
GlaxoSmithKline's defense of its Wellbutrin SR (bupropion sustained release) patents will be an early real world application of the Supreme Court's decision in the Festo case
You may also be interested in...
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims